Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
Jump to:
Preferred Name | Eltrombopag | |
Synonyms |
|
|
Definitions |
An orally active thrombopoietin receptor agonist with megakaryopoiesis stimulating activity. Eltrombopag binds to and stimulates the platelet thrombopoietin receptor (TPO-R or CD110), a member of the hematopoietin receptor superfamily. Activation of TPO-R leads to the proliferation and differentiation of megakaryocytes, thereby increasing the production of blood platelets. |
|
ID |
http://purl.obolibrary.org/obo/NCIT_C71634 |
|
ALT_DEFINITION |
The active ingredient in a drug used to treat chronic immune thrombocytopenic purpura (a condition in which platelets are destroyed by the immune system). It causes more platelets to be made in the bone marrow. It is also being studied in the treatment of low platelet counts caused by chemotherapy. It is a type of thrombopoietin receptor agonist.
|
|
CAS_Registry |
496775-61-2
|
|
Chemical_Formula |
C25H22N4O4
|
|
code |
C71634
|
|
Contributing_Source |
CTRP FDA
|
|
definition |
An orally active thrombopoietin receptor agonist with megakaryopoiesis stimulating activity. Eltrombopag binds to and stimulates the platelet thrombopoietin receptor (TPO-R or CD110), a member of the hematopoietin receptor superfamily. Activation of TPO-R leads to the proliferation and differentiation of megakaryocytes, thereby increasing the production of blood platelets.
|
|
Display_Name |
Eltrombopag
|
|
FDA_UNII_Code |
S56D65XJ9G
|
|
Has_Salt_Form | ||
Has_Target | ||
in_subset |
http://purl.obolibrary.org/obo/NCIT_C63923 |
|
label |
Eltrombopag
|
|
Legacy Concept Name |
Eltrombopag_Base
|
|
Preferred_Name |
Eltrombopag
|
|
prefixIRI |
NCIT:C71634
|
|
prefLabel |
Eltrombopag
|
|
Semantic_Type |
Amino Acid, Peptide, or Protein Pharmacologic Substance
|
|
UMLS_CUI |
C1831905
|
|
subClassOf |
Add comment
Delete | Subject | Author | Type | Created |
---|---|---|---|---|
No notes to display |
Create mapping